Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Franck Nicolini"'
Autor:
James L. Januzzi, Joseph M. Garasic, Scott E. Kasner, Vickie McDonald, Mark C. Petrie, Jonathan Seltzer, Michael Mauro, Kevin Croce, Ellin Berman, Michael Deininger, Andreas Hochhaus, Javier Pinilla-Ibarz, Franck Nicolini, Dong-Wook Kim, Daniel J. DeAngelo, Hagop Kantarjian, Jing Xu, Tracey Hall, Shouryadeep Srivastava, Daniel Naranjo, Jorge Cortes
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-25 (2022)
Abstract Background The phase 2 PACE (Ponatinib Ph+ ALL and CML Evaluation) trial of ponatinib showed robust long-term benefit in relapsed Philadelphia chromosome-positive (Ph+) leukemia; arterial occlusive events (AOEs) occurred in ≥ 25% of patien
Externí odkaz:
https://doaj.org/article/7426e5d81482431bb46fd0f35d6ca6ed
Autor:
Hyacinthe Johnson-Ansah, Benjamin Maneglier, Françoise Huguet, Laurence Legros, Martine Escoffre-Barbe, Martine Gardembas, Pascale Cony-Makhoul, Valérie Coiteux, Laurent Sutton, Wajed Abarah, Camille Pouaty, Jean-Michel Pignon, Bachra Choufi, Sorin Visanica, Bénédicte Deau, Laure Morisset, Emilie Cayssials, Mathieu Molimard, Stéphane Bouchet, François-Xavier Mahon, Franck Nicolini, Philippe Aegerter, Jean-Michel Cayuela, Marc Delord, Heriberto Bruzzoni-Giovanelli, Philippe Rousselot
Publikováno v:
Pharmaceutics, Vol 14, Iss 8, p 1676 (2022)
The registered dose for imatinib is 400 mg/d, despite high inter-patient variability in imatinib plasmatic exposure. Therapeutic drug monitoring (TDM) is routinely used to maximize a drug’s efficacy or tolerance. We decided to conduct a prospective
Externí odkaz:
https://doaj.org/article/133d20dc3fef461aa82f821be11325df
Autor:
Pierre‐Yves Dumas, Emilie Bérard, Claire Bréal, Stéphanie Dulucq, Delphine Réa, Franck Nicolini, Edouard Forcade, Melody Dufossée, Jean‐Max Pasquet, Béatrice Turcq, Audrey Bidet, Noel Milpied, Julie Déchanet‐Merville, Xavier Lafarge, Gabriel Etienne, François‐Xavier Mahon, French Intergroup in Chronic Myeloid Leukemia
Publikováno v:
Cancer Medicine, Vol 8, Iss 11, Pp 4976-4985 (2019)
Abstract Background Natural Killer (NK) cells are innate lymphoid cells that can be cytotoxic toward a large panel of solid tumors and hematological malignancies including chronic myeloid leukemia (CML). Such a cytotoxicity depends on various recepto
Externí odkaz:
https://doaj.org/article/fde024de99b941a08e4dd670a8681016
Autor:
James L. Januzzi, Joseph M. Garasic, Scott E. Kasner, Vickie McDonald, Mark C. Petrie, Jonathan Seltzer, Michael Mauro, Kevin Croce, Ellin Berman, Michael Deininger, Andreas Hochhaus, Javier Pinilla-Ibarz, Franck Nicolini, Dong-Wook Kim, Daniel J. DeAngelo, Hagop Kantarjian, Jing Xu, Tracey Hall, Shouryadeep Srivastava, Daniel Naranjo, Jorge Cortes
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/3d9cba4374b14410bb48c3c9d12799d5
Autor:
Delphine Rea, Guylaine Henry, Zena Khaznadar, Gabriel Etienne, François Guilhot, Franck Nicolini, Joelle Guilhot, Philippe Rousselot, Françoise Huguet, Laurence Legros, Martine Gardembas, Viviane Dubruille, Agnès Guerci-Bresler, Aude Charbonnier, Frédéric Maloisel, Jean-Christophe Ianotto, Bruno Villemagne, François-Xavier Mahon, Hélène Moins-Teisserenc, Nicolas Dulphy, Antoine Toubert
Publikováno v:
Haematologica, Vol 102, Iss 8 (2017)
Despite persistence of leukemic stem cells, patients with chronic myeloid leukemia who achieve and maintain deep molecular responses may successfully stop the tyrosine kinase inhibitor imatinib. However, questions remain unanswered regarding the biol
Externí odkaz:
https://doaj.org/article/67115956ca4149a996eec65e65a9b9c2
Autor:
Maroun Karam, Morgan Thenoz, Valérie Capraro, Jean-Philippe Robin, Christiane Pinatel, Agnès Lançon, Perrine Galia, David Sibon, Xavier Thomas, Sophie Ducastelle-Lepretre, Franck Nicolini, Mohamed El-Hamri, Youcef Chelghoun, Eric Wattel, Franck Mortreux
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 16, Iss 1, Pp 21-30 (2014)
Although numerous factors have been found to modulate hTERT transcription, the mechanism of its repression in certain leukemias remains unknown. We show here that DEK represses hTERT transcription through its enrichment on the hTERT promoter in cells
Externí odkaz:
https://doaj.org/article/9a70383a39c5494e816703b18ee8b225
Autor:
Maël Heiblig, Mohamed Elhamri, Isabelle Tigaud, Adriana Plesa, Fiorenza Barraco, Hélène Labussière, Sophie Ducastelle, Mauricette Michallet, Franck Nicolini, Claudiu Plesa, Eric Wattel, Gilles Salles, Xavier Thomas
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 8, Iss 0, Pp e2016009-e2016009 (2016)
Objectives: Low-dose cytarabine (LD-AraC) is still regarded as the standard of care in elderly patients with acute myeloid leukemia (AML) ‘unfit’ for intensive chemotherapy. In this study, we compared the efficacy of LD-AraC, in patients ≥ 70 y
Externí odkaz:
https://doaj.org/article/771e34dea3f946fead76ceefb1d77ecc
Autor:
Sarah Huet, Pascale Cony-Makhoul, Maël Heiblig, Isabelle Tigaud, Sophie Gazzo, Amine Belhabri, Denis Souche, Mauricette Michallet, Jean-Pierre Magaud, Sandrine Hayette, Franck Nicolini
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e106250 (2014)
Recent studies demonstrate that early molecular response to tyrosine-kinase inhibitors is strongly predictive of outcome in chronic myeloid leukemia patients and that early response landmarks may identify patients at higher risk for transformation wh
Externí odkaz:
https://doaj.org/article/498ed52ee0b7482794675902f313cfd5
Autor:
Jean-Max Pasquet, Serge Roche, Gabriel Etienne, Cédric Leroy, Paul W. Manley, Coralie Belanger, Franck Nicolini, Béatrice Turcq, Francis Belloc, Valérie Lagarde, Sandrine Hayette, François-Xavier Mahon
Supplementary Table 1 from Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a07f07a2ee0e83f0923d451598bac1e
https://doi.org/10.1158/0008-5472.22375482
https://doi.org/10.1158/0008-5472.22375482
Autor:
Jean-Max Pasquet, Serge Roche, Gabriel Etienne, Cédric Leroy, Paul W. Manley, Coralie Belanger, Franck Nicolini, Béatrice Turcq, Francis Belloc, Valérie Lagarde, Sandrine Hayette, François-Xavier Mahon
Supplementary Figure 1 from Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15ab1f3bff6bbe20196d7882c1f25cc6
https://doi.org/10.1158/0008-5472.22375485.v1
https://doi.org/10.1158/0008-5472.22375485.v1